Key Highlights

  • 7.7 percent was reported Innovative Medicine sales growth to USD 16.76 billion in the third quarter of 2026, led by Tremfya, Darzalex and Carvykti, per the October 13 company release. Johnson & Johnson (NYSE:JNJ) MedTech grew only 2.5 percent to USD 8.64 billion.
  • USD 2.59 was adjusted EPS, down 7.5 percent from USD 2.80, while reported EPS fell to USD 0.09 from USD 2.12 on a one-time talc charge. Johnson & Johnson (NYSE:JNJ) still raised full-year guidance on October 13, 2026.
  • USD 101.2 billion is the new midpoint of 2026 sales guidance, up from USD 101.1 billion, and USD 11.10 is the adjusted EPS midpoint, up USD 0.06. Those small raises help explain a fall of nearly 6 percent for Johnson & Johnson (NYSE:JNJ), per published market data.
  • USD 253.28 was the October 15 close for Johnson & Johnson (NYSE:JNJ), down 0.25 percent, with a premarket quote of USD 254.15. That is about 9.9 percent below the 52-week high of USD 281.07, simple arithmetic on two published numbers.

What the Quarter Showed

Sales were USD 25.4 billion, up 5.9 percent, with the United States up 9.1 percent and international up 1.5 percent. Innovative Medicine carried the quarter, while MedTech missed estimates in published data despite gains in electrophysiology, Shockwave, contact lenses and trauma. Reported EPS of USD 0.09 reflects a special charge for the proposed talc resolution, plus the Firefly Bio acquisition and the Sail Biomedicines collaboration, according to the release.

The Talc Charge and Portfolio Moves

On July 28, 2026 the company proposed USD 5.5 billion to resolve about 76,000 ovarian cancer lawsuits, with USD 3 billion payable in 2027 if accepted. The deal needs acceptance by 95 percent of plaintiffs, so completion is months away. Booking that cost as a special charge explains the gap between reported and adjusted EPS. The chief financial officer is reported to be leaning toward spinning out the hips and knees business, which would shrink MedTech. No decision has been announced.

Analyst Reaction and Risks

Several firms trimmed targets after the report: Morgan Stanley to USD 292 from USD 294, RBC Capital to USD 280 from USD 290, and Leerink to USD 272 from USD 276, while Bernstein raised its target to USD 270 from USD 261. Risks include slower MedTech growth, Stelara erosion and the talc acceptance threshold. The dividend of USD 5.36 a share, a 2.12 percent yield, has an ex-dividend date of November 24, 2026.

Where Things Stand

Johnson & Johnson (NYSE:JNJ) fell because a MedTech miss and a very small guidance raise outweighed strong drug growth, and because adjusted EPS declined 7.5 percent while reported EPS collapsed on the talc charge. The evidence is balanced: Innovative Medicine grew 7.7 percent, the United States grew 9.1 percent, and guidance moved up, but MedTech at 2.5 percent is the weak link. Management expects stronger MedTech in the fourth quarter and beyond. Next catalysts are any hips and knees decision, progress toward the 95 percent plaintiff acceptance threshold, and the dividend date of November 24, 2026.